AU2014352843B2 - Compositions and methods for treating pulmonary hypertension - Google Patents
Compositions and methods for treating pulmonary hypertension Download PDFInfo
- Publication number
- AU2014352843B2 AU2014352843B2 AU2014352843A AU2014352843A AU2014352843B2 AU 2014352843 B2 AU2014352843 B2 AU 2014352843B2 AU 2014352843 A AU2014352843 A AU 2014352843A AU 2014352843 A AU2014352843 A AU 2014352843A AU 2014352843 B2 AU2014352843 B2 AU 2014352843B2
- Authority
- AU
- Australia
- Prior art keywords
- tgf
- subject
- ligand trap
- ligand
- soluble recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020203110A AU2020203110A1 (en) | 2013-11-21 | 2020-05-12 | Compositions and methods for treating pulmonary hypertension |
| AU2023263573A AU2023263573A1 (en) | 2013-11-21 | 2023-11-12 | Compositions and methods for treating pulmonary hypertension |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907260P | 2013-11-21 | 2013-11-21 | |
| US61/907,260 | 2013-11-21 | ||
| PCT/US2014/066776 WO2015077540A2 (en) | 2013-11-21 | 2014-11-21 | Compositions and methods for treating pulmonary hypertension |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020203110A Division AU2020203110A1 (en) | 2013-11-21 | 2020-05-12 | Compositions and methods for treating pulmonary hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014352843A1 AU2014352843A1 (en) | 2016-06-16 |
| AU2014352843B2 true AU2014352843B2 (en) | 2020-03-05 |
Family
ID=53180397
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014352843A Active AU2014352843B2 (en) | 2013-11-21 | 2014-11-21 | Compositions and methods for treating pulmonary hypertension |
| AU2020203110A Abandoned AU2020203110A1 (en) | 2013-11-21 | 2020-05-12 | Compositions and methods for treating pulmonary hypertension |
| AU2023263573A Pending AU2023263573A1 (en) | 2013-11-21 | 2023-11-12 | Compositions and methods for treating pulmonary hypertension |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020203110A Abandoned AU2020203110A1 (en) | 2013-11-21 | 2020-05-12 | Compositions and methods for treating pulmonary hypertension |
| AU2023263573A Pending AU2023263573A1 (en) | 2013-11-21 | 2023-11-12 | Compositions and methods for treating pulmonary hypertension |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10682392B2 (enExample) |
| EP (4) | EP3071215B1 (enExample) |
| JP (4) | JP6640083B2 (enExample) |
| CN (2) | CN105934249A (enExample) |
| AU (3) | AU2014352843B2 (enExample) |
| CA (1) | CA2931309C (enExample) |
| DK (2) | DK3071215T3 (enExample) |
| ES (2) | ES2778201T3 (enExample) |
| WO (1) | WO2015077540A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105658672A (zh) | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
| CN105934249A (zh) * | 2013-11-21 | 2016-09-07 | 布里格姆及妇女医院股份有限公司 | 用于治疗肺高压的组合物和方法 |
| WO2016019368A1 (en) * | 2014-08-01 | 2016-02-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| RU2748278C2 (ru) | 2016-07-15 | 2021-05-21 | Акселерон Фарма Инк. | Композиции и способы лечения легочной гипертензии |
| JP7421338B2 (ja) * | 2016-09-27 | 2024-01-24 | エピセントアールエックス，インコーポレイテッド | 免疫調節融合タンパク質 |
| JP7231553B2 (ja) * | 2017-03-02 | 2023-03-01 | ナショナル リサーチ カウンシル オブ カナダ | Ｔｇｆ－ｂ－受容体外部ドメイン融合分子及びその使用 |
| CN110785431B (zh) | 2017-05-04 | 2024-05-07 | 阿塞勒隆制药公司 | TGF-β受体II型融合蛋白及其用途 |
| UA128306C2 (uk) | 2017-05-12 | 2024-06-05 | Джянгсу Хенгруй Медісін Ко., Лтд. | ЗЛИТІ ПРОТЕЇНИ, ЯКІ МІСТЯТЬ РЕЦЕПТОР TGF-<font face="Symbol">b</font>, І ЇХ ФАРМАЦЕВТИЧНЕ ЗАСТОСУВАННЯ |
| AU2018338612A1 (en) | 2017-09-27 | 2020-05-07 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| BR112020017382A2 (pt) | 2018-03-09 | 2021-01-26 | Agenus Inc. | anticorpos anti-cd73 e métodos de uso dos mesmos |
| US11168138B2 (en) | 2018-03-26 | 2021-11-09 | Altor Bioscience, Llc | Anti-PDL1, IL-15 and TGF-beta receptor combination molecules |
| KR102881644B1 (ko) | 2018-11-09 | 2025-11-06 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | TGF-β 수용체 융합 단백질 약학적 조성물 및 이의 용도 |
| CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁（杭州）生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 |
| CN114173806A (zh) * | 2019-07-26 | 2022-03-11 | 密歇根州立大学董事会 | 预防或治疗骨骼肌脂肪变性的方法 |
| WO2021041886A1 (en) * | 2019-08-29 | 2021-03-04 | Nantbio, Inc. | Modified n-810 and methods therefor |
| TW202128763A (zh) * | 2019-11-12 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含有ＴＧＦ－β受體的融合蛋白及其醫藥用途 |
| WO2023206188A1 (en) * | 2022-04-28 | 2023-11-02 | Wenzhou Prarucom Bio-Chemical Technology Co. | Method for alleviating pulmonary fibrosis using epidermal growth factor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048024A1 (en) * | 1997-04-18 | 1998-10-29 | Biogen, Inc. | Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| EP1087998A1 (en) | 1998-06-16 | 2001-04-04 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| JP2006502906A (ja) * | 2002-10-14 | 2006-01-26 | ソシエテ ド テクノロジー ミシュラン | 対称的な荷重分布を有するビードを備えた長期移動性タイヤ |
| EP1646655A2 (en) * | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 ligands |
| GB0514259D0 (en) | 2005-07-12 | 2005-08-17 | Renovo Ltd | Pharmaceutical compositions |
| WO2007056513A1 (en) * | 2005-11-08 | 2007-05-18 | Institute For Chemical Genomics | α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS |
| EP1998810A4 (en) | 2006-03-13 | 2009-09-02 | Univ Johns Hopkins | INCREASE OF ENDOTHELIAL THROMBORESISTENTEN |
| JP2009539842A (ja) | 2006-06-05 | 2009-11-19 | ノバルティス アクチエンゲゼルシャフト | 副甲状腺関連障害の処置におけるＴＧＦ−βアンタゴニストの使用 |
| CN100588717C (zh) | 2007-03-21 | 2010-02-10 | 中国医学科学院阜外心血管病医院 | 生长分化因子15基因多态位点在预测高血压继发左心室肥厚中的用途 |
| JP5303557B2 (ja) | 2007-08-22 | 2013-10-02 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤である２−ヘテロアリールアミノ−ピリミジン誘導体 |
| EP2037275A1 (en) | 2007-09-11 | 2009-03-18 | F. Hoffmann-La Roche AG | Differentiation of different causes of right heart failure |
| KR101008385B1 (ko) | 2008-08-01 | 2011-01-14 | 한국과학기술연구원 | 다환 방향족 탄화수소류 노출 여부 확인용 바이오마커 및이를 이용한 확인 방법 |
| CA2737271C (en) | 2008-09-17 | 2020-06-23 | National Research Council Of Canada | Hetero-multivalent binding agents for members of the tgf.beta. superfamily |
| EP2524038A4 (en) | 2010-01-12 | 2013-11-20 | Isis Pharmaceuticals Inc | MODULATION OF TRANSFORMING A GROWTH FACTOR BETA-1 EXPRESSION |
| EP2372364A1 (en) | 2010-03-31 | 2011-10-05 | Medizinische Hochschule Hannover | Biomarker for pulmonary hypertension |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US20130287688A1 (en) | 2010-11-18 | 2013-10-31 | Xtuit Pharmaceuticals, Inc. | Novel compositions and uses of anti-hypertension agents for cancer therapy |
| CN103443126B (zh) | 2011-01-06 | 2016-11-23 | 葛兰素集团有限公司 | 结合TGFβ受体II的配体 |
| CN108178789B (zh) * | 2011-04-20 | 2021-11-02 | 阿塞勒隆制药公司 | 内皮糖蛋白多肽及其用途 |
| EP3954704A1 (en) | 2011-06-03 | 2022-02-16 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
| CN104011069A (zh) | 2011-08-01 | 2014-08-27 | 塔夫茨医学中心有限公司 | 心力衰竭及相关病症的治疗 |
| CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| WO2013059879A1 (en) | 2011-10-26 | 2013-05-02 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
| WO2013188787A1 (en) | 2012-06-15 | 2013-12-19 | The General Hospital Corporation | INHIBITORS OF MICRORNAs THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF |
| EP2597466A1 (en) | 2012-06-26 | 2013-05-29 | Roche Diagniostics GmbH | Means and methods for proSP-B based diagnosis of alveolar damage in pulmonary hypertension patients |
| CN104853775B (zh) | 2012-09-26 | 2023-10-20 | 尤利乌斯·马克西米利安维尔茨堡大学 | 针对生长和分化因子15(gdf-15)的单克隆抗体 |
| MX370720B (es) | 2012-12-21 | 2019-12-20 | Aveo Pharmaceuticals Inc | Anticuerpos anti-gdf15. |
| PT2945642T (pt) | 2013-01-17 | 2024-05-27 | Medizinische Hochschule Hannover | Proteína do fator 1 para utilização no tratamento ou prevenção de doenças |
| KR101346132B1 (ko) | 2013-02-18 | 2013-12-31 | 강원대학교산학협력단 | Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-14 |
| KR101346181B1 (ko) | 2013-02-18 | 2014-01-03 | 강원대학교산학협력단 | Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-12 |
| CN105658672A (zh) * | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
| CN105934249A (zh) * | 2013-11-21 | 2016-09-07 | 布里格姆及妇女医院股份有限公司 | 用于治疗肺高压的组合物和方法 |
| EP3145493B1 (en) | 2014-05-18 | 2022-07-27 | Children's Medical Center Corporation | Methods and compositions relating to exosomes |
| RU2016147122A (ru) | 2014-06-13 | 2018-07-16 | Новартис Аг | Применение серелаксина для снижения gdf-15 |
| US20170137505A1 (en) | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
| WO2016019368A1 (en) | 2014-08-01 | 2016-02-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
-
2014
- 2014-11-21 CN CN201480073820.1A patent/CN105934249A/zh active Pending
- 2014-11-21 EP EP14864524.5A patent/EP3071215B1/en active Active
- 2014-11-21 DK DK14864524.5T patent/DK3071215T3/da active
- 2014-11-21 AU AU2014352843A patent/AU2014352843B2/en active Active
- 2014-11-21 CN CN202511199453.6A patent/CN120919282A/zh active Pending
- 2014-11-21 EP EP20150385.1A patent/EP3685848B1/en active Active
- 2014-11-21 EP EP24166565.2A patent/EP4417255A3/en active Pending
- 2014-11-21 ES ES14864524T patent/ES2778201T3/es active Active
- 2014-11-21 CA CA2931309A patent/CA2931309C/en active Active
- 2014-11-21 DK DK20150385.1T patent/DK3685848T3/da active
- 2014-11-21 WO PCT/US2014/066776 patent/WO2015077540A2/en not_active Ceased
- 2014-11-21 JP JP2016533067A patent/JP6640083B2/ja active Active
- 2014-11-21 US US15/037,852 patent/US10682392B2/en active Active
- 2014-11-21 EP EP21190858.7A patent/EP4005585B1/en active Active
- 2014-11-21 ES ES20150385T patent/ES2902533T3/es active Active
-
2019
- 2019-12-25 JP JP2019233811A patent/JP6952100B2/ja active Active
-
2020
- 2020-04-17 US US16/851,287 patent/US11951156B2/en active Active
- 2020-05-12 AU AU2020203110A patent/AU2020203110A1/en not_active Abandoned
-
2021
- 2021-09-27 JP JP2021156343A patent/JP7474729B2/ja active Active
-
2023
- 2023-11-12 AU AU2023263573A patent/AU2023263573A1/en active Pending
-
2024
- 2024-03-01 US US18/593,002 patent/US20240366720A1/en active Pending
- 2024-04-15 JP JP2024065676A patent/JP2024096891A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048024A1 (en) * | 1997-04-18 | 1998-10-29 | Biogen, Inc. | Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240366720A1 (en) | Compositions and methods for treating pulmonary hypertension | |
| US11932677B2 (en) | Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseases | |
| US12187783B2 (en) | Methods for treating muscle wasting and bone disease using novel hybrid ActRIIB ligand trap proteins | |
| KR20230169124A (ko) | Actrii-alk4 길항제 및 심부전을 치료하는 방법 | |
| CN116917330A (zh) | 激活蛋白/TGF-β和RANKL的双功能拮抗剂及其用途 | |
| CN116744959A (zh) | 肿瘤坏死因子-α和转化生长因子-β的双功能拮抗剂及其用途 | |
| BR112017022658B1 (pt) | Proteína isolada, composição farmacêutica compreendendo a mesma, e uso da composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |